Cetuximab activity in dysplastic lesions of the upper aerodigestive tract.

ABSTRACT:

Background

High risk head and neck mucosal premalignancy has a malignant conversion rate of up to 40%, despite adequate surgical therapy. Epidermal Growth Factor Receptor (EGFR) blocking agents, including cetuximab, have shown activity in head and neck squamous cell carcinoma (HNSCC) and have potential for therapy in high risk premalignancy.

Methods

We conducted a randomized, prospective, phase II clinical trial to determine the effects of cetuximab on patients with high risk premalignancy. Patients were randomized to treatment with cetuximab 400mg/m(2) on week one followed by 250mg/m(2) on week 2-8 or observation, with the option for crossover to cetuximab therapy for patients originally randomized to the observation arm.

Results

Two of 19 enrolled patients did not c

SUBMITTER: Khan Z 

PROVIDER: S-EPMC7751887 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature